Sunday, May 5, 2024

Nutrition Center

No Result

View All Result

Nutrition Center

No Result

View All Result

Home Tag Eisai

Tag: Eisai

Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

STOCKHOLM, Might 9, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) accomplice Eisai introduced right now that they've ...

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY

TOKYO and CAMBRIDGE, Mass., Might 9, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen ...

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

STOCKHOLM, March 4, 2022 /PRNewswire/ -- BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) associate Eisai has initiated a submission ...

Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer’s Disease Under The Accelerated Approval Pathway

September 28, 2021

TOKYO and CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Eisai Company, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...

Recent Posts

© 2021 Nutrition Center.

No Result

View All Result

© 2021 Nutrition Center.